Tesa vs HGH comes down to how each raises growth hormone. Compare tesamorelin and somatropin on mechanism, dosing, cost, side effects, and legal status.
Tesamorelin (often shortened to tesa) and HGH are two different routes to the same endpoint: more growth hormone signaling in the body. Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog that prompts the pituitary to release the body's own growth hormone, while HGH is recombinant somatropin injected directly. Tesamorelin is FDA-approved only for HIV-associated lipodystrophy, and HGH is FDA-approved only for specific diagnosed conditions such as pediatric and adult growth hormone deficiency.
What Is Tesamorelin (Tesa)?
Tesamorelin is a 44-amino-acid GHRH analog sold under the brand name Egrifta. It binds GHRH receptors in the pituitary, increasing endogenous growth hormone release, which in turn raises IGF-1.
- Class: GHRH analog peptide
- Approved use: Reduction of excess abdominal fat in adults with HIV-associated lipodystrophy
- Typical researched dose: 1-2 mg subcutaneously once daily
- Half-life: Roughly 26-38 minutes
- Form: Lyophilized powder reconstituted for injection
Tesamorelin works through the body's own feedback loops. Because the pituitary still regulates output, growth hormone release stays pulsatile rather than arriving as one large spike. That difference sits at the center of most tesa vs hgh debates.
What Is HGH (Somatropin)?
HGH, or human growth hormone, is a 191-amino-acid protein produced by the pituitary gland. Pharmaceutical HGH is manufactured with recombinant DNA technology and prescribed as somatropin. In practice, hgh 191aa vs somatropin describes the same recombinant molecule: 191aa refers to the 191-amino-acid sequence, and somatropin is the generic drug name.
Exogenous HGH bypasses the pituitary entirely. Injecting somatropin raises serum growth hormone directly, which then stimulates IGF-1 production in the liver. Because the dose is set by the syringe rather than by feedback, levels can climb higher than the body would produce on its own.
Tesa vs HGH: Side-by-Side Comparison
| Feature | Tesamorelin (Tesa) | HGH (Somatropin) |
|---|---|---|
| Mechanism | Stimulates pituitary GH release | Supplies GH directly |
| Molecular size | 44-amino-acid peptide | 191-amino-acid protein |
| GH pattern | Pulsatile, feedback-limited | Large non-physiologic spike |
| Typical research dose | 1-2 mg daily | 1-4 IU daily, highly variable |
| FDA-approved indication | HIV-associated lipodystrophy | GH deficiency and other specific diagnoses |
| Main research interest | Visceral fat, IGF-1 response | Body composition, growth, recovery |
| Monitoring | IGF-1, glucose, injection sites | IGF-1, glucose, thyroid, joint symptoms |
| US legal status | Prescription only | Prescription only, Schedule III |
How the Two Compare on Results
Head-to-head human trials of tesamorelin versus somatropin are essentially nonexistent. Most comparisons are assembled from separate studies of each compound, so any "which is stronger" answer is an inference rather than a measured result.
What the published literature does support is that both compounds can raise IGF-1 and reduce visceral fat in specific populations over months of use. Tesamorelin's approved trial data come from adults with HIV and central fat accumulation, while somatropin's data come largely from diagnosed growth hormone deficiency.
Neither compound is approved for general weight loss, athletic performance, or anti-aging in healthy adults. Extending either beyond its labeled use is off-label and carries risks that grow with dose and duration.
Dosing, Cost, and Practical Differences
- Injection frequency: Tesamorelin is usually studied at once daily; somatropin is often split into daily or several-times-weekly protocols.
- Cost: Brand-name tesamorelin can run several thousand dollars per month in the US, and prescription somatropin is comparably expensive without insurance.
- Storage: Both require refrigeration after reconstitution and careful handling.
- Bloodwork: IGF-1 is the standard marker for tracking response to either compound.
Cost is one reason people researching growth hormone pathways look at cheaper alternatives. Compounds such as AOD 9604 and the HGH fragment are studied for fat metabolism rather than full GH elevation, and a frequent entry point into that literature is aod 9604 vs hgh, which sets a fragment-based approach against full recombinant hormone.
Side Effects and Safety
Tesamorelin and somatropin share several side effects because both increase GH and IGF-1 signaling. Injection-site reactions, joint pain, fluid retention, and elevated blood sugar are reported with both.
Tesamorelin carries an FDA warning about increased diabetes risk plus cautions around injection-site reactions and hypersensitivity. Somatropin labeling warns about intracranial hypertension and glucose intolerance, and some patient populations show increased mortality at high doses.
Anyone considering either compound should have baseline IGF-1, fasting glucose, and HbA1c testing and work with a licensed clinician. Self-dosing with research-grade peptides sold online is a real safety concern because purity and identity are not guaranteed.
Legal and Regulatory Status in the US
Tesamorelin is a prescription drug in the United States, available as Egrifta and only for its approved indication. HGH is a Schedule III controlled substance under federal law and is legal only with a prescription for an accepted medical diagnosis.
Buying HGH or tesamorelin without a prescription is illegal in the US, and importing them for personal use does not make it legal. Research-only peptide listings are not intended for human use.
Related Comparisons in Growth Hormone Research
Growth hormone research rarely stops at one compound. Many readers move from tesa vs hgh into pairings that isolate a single effect, such as cjc-1295 ipamorelin vs hgh, which compares a GHRH and GHRP stack against direct hormone replacement.
Fat-loss-focused readers tend to look at hgh fragment 176-191 vs somatropin, since the fragment is designed to target lipolysis without the full growth-promoting effects of intact hormone. The same question shows up in reverse as hgh fragment 176-191 vs aod 9604, where both compounds zero in on the fat-mobilizing portion of the GH molecule instead of systemic GH elevation.
The Bottom Line
Tesamorelin and HGH both raise growth hormone signaling, but they do it in fundamentally different ways: one coaxes the pituitary, the other replaces it. Tesamorelin is FDA-approved for HIV-associated lipodystrophy only, and somatropin is FDA-approved for specific growth hormone-related diagnoses only. Neither is a safe or legal option for general fat loss or performance enhancement without medical supervision.
Frequently Asked Questions
Is tesamorelin the same thing as HGH?
No. Tesamorelin is a GHRH analog peptide that stimulates your own pituitary to release growth hormone, while HGH is recombinant somatropin injected directly into the body. They both raise IGF-1, but tesamorelin keeps release pulsatile and feedback-controlled, whereas injected HGH bypasses that regulation.
Which is stronger, tesa or HGH?
There are no head-to-head human trials, so no one can answer this with data. Injected somatropin raises serum growth hormone more directly and predictably because the dose is controlled by the syringe, while tesamorelin's effect depends on how well your pituitary responds. Strength also depends heavily on dose, duration, and individual response.
Can you buy tesamorelin or HGH without a prescription in the US?
No. Tesamorelin is prescription-only and sold as Egrifta for HIV-associated lipodystrophy, and HGH is a Schedule III controlled substance that requires a prescription for a recognized diagnosis. Buying either without a prescription is illegal in the United States, and research-grade peptides sold online are not intended for human use.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.